Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Large Drop in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 263,542 shares, a drop of 65.6% from the June 15th total of 765,484 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily trading volume, of 424,964 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Trading of Cel-Sci

Several hedge funds and other institutional investors have recently modified their holdings of CVM. US Bancorp DE acquired a new stake in shares of Cel-Sci in the third quarter worth $80,000. HighTower Advisors LLC acquired a new position in Cel-Sci during the fourth quarter valued at $53,000. HRT Financial LP purchased a new stake in Cel-Sci in the 4th quarter worth about $60,000. XTX Topco Ltd purchased a new stake in Cel-Sci in the 4th quarter worth about $66,000. Finally, Renaissance Technologies LLC acquired a new stake in Cel-Sci during the 4th quarter worth about $81,000. Institutional investors and hedge funds own 12.08% of the company’s stock.

Cel-Sci Price Performance

CVM stock opened at $1.38 on Monday. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $13.48. The company’s 50 day simple moving average is $1.34 and its 200-day simple moving average is $3.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. The firm has a market capitalization of $24.12 million, a P/E ratio of -0.14 and a beta of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.